Evidence map›Paper›PMID 38805639›Full record

ArticleBlood2024

Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of the cell cycle.

Carys S Johnson, Matthew Williams, Kendig Sham, Serena Belluschi, Wenjuan Ma, Xiaonan Wang, Winnie W Y Lau, Kerstin B Kaufmann, Gabriela Krivdova, Emily F Calderbank and 17 more

Abstract read
In one paragraph

Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. ATP2B1 expression identifies human hematopoietic stem cells with superior repopulation and self-renewal.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Carys S JohnsonWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Matthew WilliamsWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Kendig ShamWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-8360-2407
Serena BelluschiWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-2328-255X
Wenjuan MaWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0009-0004-3642-0493
Xiaonan WangWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-3759-778X
Winnie W Y LauWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-1209-1854
Kerstin B KaufmannPrincess Margaret Cancer Center, University Health Network, Toronto, Canada.ORCID 0000-0001-5013-6123
Gabriela KrivdovaPrincess Margaret Cancer Center, University Health Network, Toronto, Canada.ORCID 0000-0002-7075-6124
Emily F CalderbankWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-9559-6593
Nicole MendeWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-5078-2333
Jessica McLeodPrincess Margaret Cancer Center, University Health Network, Toronto, Canada.
Giovanna ManticaWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-7429-7236
Juan LiWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Charlotte Grey-WilsonWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-3854-9771
Michael DrakopoulosWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8219-5136
Shaaezmeen BasheerWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Shubhankar SinhaWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Evangelia DiamantiWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Christina BasfordCell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom.
Nicola K WilsonWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-0865-7333
Steven J HoweCell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom.
John E DickPrincess Margaret Cancer Center, University Health Network, Toronto, Canada.ORCID 0000-0002-9527-8317
Berthold GöttgensWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-6302-5705
Anthony R GreenWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-9795-0218
Natalie FrancisCell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom.ORCID 0009-0002-9696-6004
Elisa LaurentiWellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-9917-9092

Funding

Cancer Research UK 21762Wellcome Trust 107630
6 · The paper itself

Abstract

abstractLoss of long-term hematopoietic stem cell (LT-HSC) function ex vivo hampers the success of clinical protocols that rely on culture. However, the kinetics and mechanisms through which this occurs remain incompletely characterized. In this study, through time-resolved single-cell RNA sequencing, matched in vivo functional analysis, and the use of a reversible in vitro system of early G1 arrest, we defined the sequence of transcriptional and functional events that occur during the first ex vivo division of human LT-HSCs. We demonstrated that the sharpest loss in LT-HSC repopulation capacity happens early on, between 6 and 24 hours of culture, before LT-HSCs commit to cell cycle progression. During this time window, LT-HSCs adapt to the culture environment, limit the global variability in gene expression, and transiently upregulate gene networks involved in signaling and stress responses. From 24 hours, LT-HSC progression past early G1 contributes to the establishment of differentiation programs in culture. However, contrary to the current assumptions, we demonstrated that the loss of HSC function ex vivo is independent of cell cycle progression. Finally, we showed that targeting LT-HSC adaptation to culture by inhibiting the early activation of JAK/STAT signaling improves HSC long-term repopulating function ex vivo. Collectively, our study demonstrated that controlling early LT-HSC adaptation to ex vivo culture, for example, via JAK inhibition, is critically important to improve HSC gene therapy and expansion protocols.

Indexed as

Cell CycleHematopoietic Stem CellsAdaptation, PhysiologicalCell Culture TechniquesCell DifferentiationCells, CulturedHumansSignal Transduction

Identifiers

PMID38805639
PMCPMC7616366

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.